Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 5461-5470 Newer>

The Motley Fool February 25, 2009 Brian Orelli	Will It Ever End? Genentech's Special Committee of its Board of Directors recommended that investors reject Roche's most recent tender offer.
The Motley Fool February 24, 2009 Brian Orelli	Back to the Red, but Not for Long After a few quarters in the black, Onyx Pharmaceuticals slips back into the red, reporting a loss of $30 million for the fourth quarter.
The Motley Fool February 24, 2009 Brian Orelli	Medtronic Hearts Acquisitions Medical device maker Medtronic pays a little over $1 billion for two acquisitions in one day.
The Motley Fool February 24, 2009 Brian Orelli	Pfizer: Diversified Dreams, Dubious Decisions Pfizer's CEO Jeffrey Kindler said he wants to make his company more like Johnson & Johnson and Abbott Labs, which aren't dependent on one product for success.
The Motley Fool February 23, 2009 Brian Orelli	Genzyme Playing Defense The latest good news from this company won't help the top line much.
The Motley Fool February 23, 2009 Brian Orelli	The DOJ v. Johnson & Johnson The U.S. Department of Justice is joining a lawsuit against the health care giant over the company's marketing of heart failure drug Natrecor.
The Motley Fool February 23, 2009 Brian Orelli	Why Do You Hate Health-Care Companies So Much? Members of Congress plan to introduce a bill that would give patients legal recourse against medical device companies making drug-eluting stents, essentially nullifying a previous Supreme Court decision.
Wired Alex Salkever	Doc in a Box -- New Surgery Bot Prepares for Battle Nobody wants to have surgery on a battlefield; the idea of having it performed by a robot spider probably doesn't make it sound any less harrowing.
Wired Bob Parks	Drill Delivers Drugs Straight to the Marrow Sometimes a good vein is hard to find -- especially when you're bouncing around in an ambulance or working on a convulsing junkie.
The Motley Fool February 20, 2009 Brian Orelli	Generic Synergies, Stellar Earnings Growth Mylan is working through its growing pains. The company doubled in size when it bought Merck KGaA's generic drug business, after it had already purchased Indian generic drugmaker Matrix Laboratories. In an instant, it became a global player.
<Older 5461-5470 Newer> Return to current articles.